GLOBAL SYNTHETIC DATA IN HEALTHCARE MARKET (2026 - 2030)

In 2025, the Synthetic Data in Healthcare Market was valued at approximately USD 1.18 Billion. It is projected to grow at a CAGR of around 26.4% during the forecast period of 2026–2030, reaching an estimated USD 3.81 Billion by 2030.

The Global Synthetic Data in Healthcare Market is the commercial market for software platforms, tools, and services that create synthetic data sets that mirror the statistical nature of actual healthcare data without sharing personally identifiable information. These technologies are applied to develop algorithms, validate digital health solutions, model scenarios, and speed up research when real data is limited, costly, or time-consuming. This market encompasses solutions designed for structured data, images, text, monitoring data, deployment support, and services. It does not include traditional analytics tools, general cloud storage, and synthetic data applications not focused on health care use cases.

The market has evolved from trial usage to real-world implementation as the need to scale artificial intelligence (AI) projects in healthcare has grown, with new risks to data privacy, security, and regulatory compliance. Synthetic data is now seen by many healthcare providers and life sciences firms as a means to overcome the bottleneck of delays due to siloed systems, a lack of labeled data, and slow approvals. Improvements in generative models also allow for more realism and usefulness, enabling synthetic datasets to be used for clinical modeling, image development, and software validation. Meanwhile, customers have grown discerning, with an emphasis on governance, bias management, and metrics on performance.

For leaders, the market is shaping investments and the implementation of data strategies. Managers need to decide between building or buying capabilities from focused vendors, which model to adopt for different risk profiles, and where synthetic data can deliver the quickest wins in terms of efficiency gains. Market intelligence supports buyers to navigate vendor over-promises, identify the use cases with the greatest value, and prioritize investments in line with compliance and growth strategy.

Key Market Insights

• By late 2025, half the leaders implemented gen AI.
• Just 19% had agentic AI—a wave two.
• 82% anticipated good returns on gen AI investments.
• In 2024, 76% of radiology and 950 AI devices were approved in the U.S.
• Radiology NMPA approvals grew by 221 in 2023, cementing its lead.
• In 2024 hospitals used 71% predictive AI (up from 66%).
• India issued 73.98 crore ABHA IDs in 36 states and 786 districts.
• India connected 49.06 crore data records to ABHA for better continuity of care.
• Health data regulations in Europe progressed in 2015 in 27 countries.
• Public hospital productivity improved 2.7% in the UK (April 2024-March 2025).
• Over 70% of C-suites focused on productivity in 2025.
• Singapore created 2 public health interoperability standards in 2025.
• Singapore invested more than S$1 billion in public AI research by 2030.

Research Methodology

Scope & definitions

• Covers revenue generated from synthetic data software platforms, tools, and related services used in healthcare applications; excludes general-purpose non-healthcare synthetic data and unrelated analytics revenue.
• Geography: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa; historical review, base year, and forecast period defined in-report.
• Segmentation: By Data Type, Application, Deployment Mode, End User, and Region.
• Standardized data dictionary, vendor mapping rules, and revenue-allocation logic applied to prevent overlap and double counting.

Evidence collection (primary + secondary)

• Primary research across the value chain: technology vendors, cloud providers, healthcare IT firms, hospitals, pharma/biotech companies, researchers, distributors, and channel partners.
• Structured interviews with executives, product leaders, procurement teams, and domain specialists for demand, pricing, adoption, and pipeline validation.
• Secondary sources include company annual reports, investor presentations, audited filings, product documentation, peer-reviewed journals, WHO, FDA, NIH, OECD, and relevant regulators/standards bodies/industry associations specific to Global Synthetic Data in Healthcare Market (named in-report).
• Key claims are supported with verifiable, source-linked evidence inside the report.

Triangulation & validation

• Market sizing uses bottom-up aggregation of company revenues and top-down benchmarking from healthcare AI/data spending pools.
• Results reconciled to financial disclosures where applicable, then stress-tested through regional and segment splits.
• Conflicting-source resolution, outlier screening, and interview revalidation reduce bias.

Presentation & auditability

• Transparent assumptions, formulas, and CAGR calculations documented in-report.
• Traceable tables/charts with cited sources, version controls, and analyst review logs maintained.

Global Synthetic Data in Healthcare Market Drivers

Growing AI use calls for secure health data to train AI.

The pace of artificial intelligence initiatives is increasing in healthcare, but projects often fail to move forward due to a lack of available data. Synthetic data allows teams to train, test, and validate models without risking privacy breaches, speeding up and enabling deployment. This is particularly important for imaging, analytics, and workflow automation initiatives that require large amounts of data.

New governance considerations impact access models.

Health leaders and CIOs are under increased scrutiny for data management, controls, and the use of sensitive data. Current sharing practices can slow modernization due to the time required for approvals, de-identification processes, and coordination between teams for analytics initiatives. Synthetic data provides a more agile model by providing an approach to collaborate with less risk of access to identifiable data.

Scalable data is needed to automate research processes.

Research and development (R&D) teams need to accelerate timelines, boost productivity, and automate tedious tasks across the lifecycle of healthcare innovation. Synthetic data helps in achieving these objectives by providing scalable data for modeling, simulation, scenario testing, and software development in the absence of real-world data.

Global Synthetic Data in Healthcare Market Restraints

Despite the interest, uptake of synthetic data in healthcare lags. Purchasers are skeptical of whether synthetic datasets capture clinical complexity and bias. Standards vary, dragging down the regulated use cases and procurement process. Old systems make it difficult to share data across hospitals and networks. Skilled talent is scarce.

Global Synthetic Data in Healthcare Market Opportunities

Healthcare providers and researchers are opening up lucrative opportunities for vendors that accelerate AI development while maintaining privacy. Increasingly, people want tools to create realistic images and clinical and monitoring data for training models and testing software. Pharma wants improved drug design and discovery. Health providers seek safer digital analytics upgrades, avoiding privacy problems.

How this market works end-to-end

1. Need Defined
   An organization identifies blocked AI, research, or testing projects caused by poor data access.
2. Data Type Chosen
   Teams prioritize tabular records, medical images, clinical text, or time-series monitoring data.
3. Use Case Ranked
   They focus on imaging AI, clinical trials, drug discovery, population health, or software testing.
4. Governance Screen
   Privacy, consent, security, and residency rules shape deployment choices.
5. Platform Selection
   Buyers compare cloud-based, hybrid, and on-premises solutions.
6. Model Validation
   Synthetic outputs are tested against utility, bias, drift, and privacy leakage risk.
7. Business Rollout
   Hospitals, pharma firms, research institutes, and healthcare IT vendors deploy by function.
8. Regional Scaling
   Programs expand across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa based on regulatory fit.

Why this market matters now

Healthcare wants AI results now, but data access remains slow. Legal review cycles, fragmented systems, ransomware exposure, and public trust concerns have raised the cost of using live patient data. At the same time, boards expect measurable AI returns.

That creates a timing problem. Wait too long and competitors improve faster. Move too fast and poor synthetic data damages models, creates compliance risk, or wastes capex.

The real market shift is not demand for “more AI.” It is demand for usable, governed data supply. Synthetic data increasingly sits in that supply chain. Buyers need clarity on where it works, where it fails, and which segments produce durable revenue.

What matters most when evaluating claims in this market

The decision lens

1. Define Boundary
   Verify whether you need imaging, text, tabular, or mixed data. Avoid buying a broad tool for a narrow need.
2. Measure Utility
   Compare downstream model results using synthetic versus real data.
3. Test Privacy
   Demand leakage tests, access controls, and governance evidence.
4. Check Integration
   Stress-test fit with EHR, PACS, cloud, and analytics systems.
5. Map Exposure
   Review regional data rules, cyber posture, and vendor concentration.
6. Model Economics
   Compare subscription, compute, services, and internal staffing costs.
7. Time Entry
   Watch for budget freezes, policy shifts, or delayed AI programs that change timing.

The contrarian view

Many buyers overestimate the market by counting all healthcare AI spend as synthetic data demand. That is wrong.

Some vendors blur synthetic data with anonymization, simulation, or data augmentation. These are related, not identical.

Another common error is assuming more synthetic records equal better outcomes. Low-quality synthetic data can amplify bias or reduce model usefulness.

Regional demand is also not uniform. A one-size global forecast often ignores local policy friction, hospital IT maturity, and cloud restrictions.

Finally, service revenue and software revenue are often mixed, causing double counting and weak comparisons.

Practical implications by stakeholder

Healthcare Providers

• Prioritize imaging, workflow testing, and analytics use cases.
• Align procurement with privacy and cyber teams.

Pharma & Biotech

• Use synthetic cohorts to speed research design.
• Verify acceptance limits for regulated workflows.

Healthcare IT Vendors

• Shorten product testing cycles with synthetic environments.
• Build differentiated AI features faster.

Investors & Strategy Teams

• Separate hype from repeatable enterprise demand.
• Watch retention, deployment time, and segment mix.

Researchers & Academia

• Expand collaboration where real data sharing is restricted.
• Validate representativeness before publication use.

GLOBAL SYNTHETIC DATA IN HEALTHCARE MARKET

Global Synthetic Data in Healthcare Market Segmentation

Global Synthetic Data in Healthcare Market – By Data Type

• Introduction/Key Findings
• Tabular Data
• Image Data
• Text Data
• Time-Series Data
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Tabular data has a 38.6% share in 2030, as claims data lab data analytics require. Synthetic structured data is used to speed up model testing and avoid privacy risks and preparation time delays in hospitals and insurers worldwide today, now marketing safely each day.

Radiology, pathology, and oncology AI models need synthetic scans for training; hence, the fastest-growing image data is at a 29.4% CAGR to 2030. Hospitals use synthetic scans for accuracy reduction in labeling costs and time to market globally, now quickly continuing.

Global Synthetic Data in Healthcare Market – By Application

• Introduction/Key Findings
• Clinical Trials & Research
• Medical Imaging
• Drug Discovery & Development
• Population Health Management
• Healthcare Analytics & AI Training
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Clinical trials research has a 30.8% share in 2030 as pharmaceutical companies look for quicker cohort and protocol design cycle times. Sponsors faced with cost-cutting use synthetic patients to reduce feasibility time and test scenarios today, now globally, with ongoing teams everywhere.

Medical imaging is the fastest-growing, with a CAGR of almost 30.1% CAGR by 2030, driven by radiology backlogs and the increasing need for diagnostic automation globally. Synthetic images help vendors train algorithms faster, reduce labeling costs, and enable safer algorithm rollouts in hospitals this year.

Global Synthetic Data in Healthcare Market – By Deployment Mode

• Introduction/Key Findings
• On-Premises
• Cloud-Based
• Hybrid
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Synthetic Data in Healthcare Market – By End User

• Introduction/Key Findings
• Pharmaceutical & Biotechnology Companies
• Healthcare Providers
• Research & Academic Institutes
• Healthcare IT Companies
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Synthetic Data in Healthcare Market– Regional Analysis

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America leads with 41.2% market share in 2030, with established IT spending and early adoption of AI across the region. Vendor ecosystems and tooling for data privacy sustain procurement levels at providers, payers, and pharma today, now here strong.

APAC is the fastest-growing region at 31.2% CAGR to 2030, with digital hospital buildouts and increasing investment in analytics. Data sovereignty regulations and new projects drive new demand for scalable synthetic platforms in new markets this year.

Latest Market News

On Apr 07, 2026, the SYNTHIA consortium said the consortium's healthcare synthetic data program is making progress in research across 6 disease domains through EU grant agreement 101172872. This program is still dedicated to privacy-safe data for AI and clinical research.

Mar 05, 2026, Kyndryl found 55% of healthcare institutions were worried they wouldn't be able to keep up with regulation changes, and only 30% felt ready for change. It highlights the need for governed synthetic data environments for compliant and scalable AI.

On Feb 04, 2026, SYNTHIA noted synthetic data for cancer research with support for global cancer innovation and 6 disease domains and grant framework 101172872. The release is a reflection of continued growth in synthetic data for clinical research use.

On Jan 29, 2026, a key industry research report highlighted the overall synthetic test data market growing from 1.81 billion USD in 2024 to 2.46 billion USD in 2025. Health was listed as one of the key regulated industries for privacy-safe data for AI.

On Oct 12, 2025, researchers described a hybrid model of synthetic clinical data for tabular data with Wasserstein distance as low as 0.001 and downstream classifier accuracy up to 94%. This potentially indicates greater commercial viability for healthcare analytics and AI training applications.

Mar 26, 2025, researchers studying synthetic health data found reidentification risks still hinder data sharing, despite the increased use. The 2025 paper had 9 authors and was published formally in 2025, mentioning that governance is an ongoing consideration for buyers.

On Oct 13, 2024, GE HealthCare joined the SYNTHIA consortium and disclosed the project would test synthetic data in 6 diseases and for various data types. GE HealthCare also stated its business size at USD 19.7 billion with 53,000 employees to highlight corporate efforts in the field.

The Innovative Health Initiative launched SYNTHIA on Sep 11, 2024, to develop and validate synthetic data tools for imaging, genomics, clinical notes, and mobile health data under project number 101172872. This was one of the first major public-private synthetic data projects of the cycle.

Key Players

1. MDClone
2. Syntegra
3. Gretel Labs
4. Mostly AI
5. Hazy
6. Betterdata
7. Synthea
8. DataGen Technologies
9. Replica Analytics
10. NVIDIA Corporation